In most cases, these anti-tumor agents are represented by small molecule kinase inhibitors or monoclonal antibodies that target pathways involved in the proliferation and survival of tumor cells, such as, for example, those triggered by receptor tyrosine kinases (RTK), including the epidermal growth factor receptor (EGFR) and HER2, or by downstream effectors, including the kinases BRAF and ABL. This evidence concerns the gene BRAF and neoplasm.